ReviewAnti-cancer agents in medicinal chemistry2008
Is Cdc25 a druggable target?
Review in Anti-cancer agents in medicinal chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression.Scientific reports · 2019Article
- Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines.Marine drugs · 2018Article
- Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.Oncotarget · 2014Article
- Article
- GeneFriends: an online co-expression analysis tool to identify novel gene targets for aging and complex diseases.BMC genomics · 2012Article
- The role of Cdc25A in the regulation of cell proliferation and apoptosis.Anti-cancer agents in medicinal chemistry · 2012Review
- Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.Gastroenterology · 2012Article
- CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples.Journal of neuro-oncology · 2010Article
- G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).Experimental and therapeutic medicine · 2010Article
- A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.Cancer prevention research (Philadelphia, Pa.) · 2010Article
- Targeting protein tyrosine phosphatases for anticancer drug discovery.Current pharmaceutical design · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Proper control of cell cycle progression requires the functionality of a small family of activating phosphatases termed Cdc25, which have been implicated in cancer and Alzheimer's disease. These protein tyrosine phosphatases are therefore recognized as attractive molecular targets for small molecules. We review the rationale, approaches, progress and challenges for developing small molecule inhibitors of the Cdc25 family. A number of potential chemical probes are discussed and their characteristics are summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.